openPR Logo
Press release

Hepatocellular Carcinoma Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

07-10-2024 01:08 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Hepatocellular Carcinoma Pipleine

Hepatocellular Carcinoma Pipleine

Hepatocellular Carcinoma companies are Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, more.
(Albany, USA) As per DelveInsight's assessment, globally, about 90+ key pharma and biotech companies are working on 95+ pipeline drugs in the Hepatocellular Carcinoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Hepatocellular Carcinoma Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Hepatocellular Carcinoma Therapeutics Market. The report provides a detailed description of the Hepatocellular Carcinoma drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Hepatocellular Carcinoma Clinical Trial Activities and Regulatory Developments in the domain @ Hepatocellular Carcinoma Pipeline Analysis [https://www.delveinsight.com/report-store/hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some facts of the Hepatocellular Carcinoma Pipeline are:

* Hepatocellular Carcinoma Companies across the globe are diligently working toward developing novel Hepatocellular Carcinoma treatment therapies with a considerable amount of success over the years.
* Hepatocellular Carcinoma companies working in the treatment market are Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCap Zoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others, are developing therapies for the Hepatocellular Carcinoma treatment
* Emerging Hepatocellular Carcinoma therapies in the different phases of clinical trials are Namodenoson, SRF388, Porustobart, Fisogatinib, STP705, and others are expected to have a significant impact on the Hepatocellular Carcinoma market in the coming years.

Hepatocellular Carcinoma (HCC) Pipeline Analysis

The report provides insights into:

* The report provides detailed insights into the key companies that are developing Hepatocellular Carcinoma therapies.
* The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatocellular Carcinoma treatment.
* It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* It navigates the emerging Hepatocellular Carcinoma drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Hepatocellular Carcinoma treatment market.

Learn More about the Clinical and Commercial Development Activities in the Hepatocellular Carcinoma Therapeutics Domain @ Hepatocellular Carcinoma FDA Approvals and Advancements [https://www.delveinsight.com/report-store/hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Hepatocellular Carcinoma (HCC) Therapeutics Analysis

About 90+ notable companies are actively involved in developing therapies for Hepatocellular Carcinoma (HCC). Among them, Can-Fite BioPharma stands out as a key player, advancing its HCC drug candidates to the most advanced stage, Phase III.

Hepatocellular Carcinoma Companies in the Therapeutics Market Include:

Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCap Zoom Biosciences, Eutilex, Polaris Pharmaceuticals, and OriCell Therapeutics are the leading pharma giants shaping the landscape of the Hepatocellular Carcinoma Therapeutic Market.

Emerging and Marketed Hepatocellular Carcinoma Therapies Covered in the Report Include:

* Namodenoson: Can-Fite BioPharma
* SRF388: Surface Oncology
* Porustobart: Harbour BioMed
* Fisogatinib: CStone Pharmaceuticals
* STP705: Sirnaomics
* And Many Others

Get an in-depth Assessment of the Emerging Therapies and Hepatocellular Carcinoma Companies Actively Working in the Market @ Hepatocellular Carcinoma Drugs in Pipeline [https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Hepatocellular Carcinoma Drugs Uptake

The Report Covers the Emerging Hepatocellular Carcinoma Therapies Under Different Phases of Clinical Development Like -

* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued and inactive candidates

Route of Administration

Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Molecule Type

Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Request for Sample PDF to Understand More About the Hepatocellular Carcinoma Treatment Outlook and Future Perspectives @ Hepatocellular Carcinoma Drugs and Therapies [https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Content

1. Report Introduction

2. Executive Summary

3. Hepatocellular Carcinoma Current Treatment Patterns

4. Hepatocellular Carcinoma - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Hepatocellular Carcinoma Late-Stage Products (Phase-III)

7. Hepatocellular Carcinoma Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Hepatocellular Carcinoma Discontinued Products

13. Hepatocellular Carcinoma Product Profiles

14. Hepatocellular Carcinoma Companies

15. Hepatocellular Carcinoma Drugs

16. Dormant and Discontinued Products

17. Hepatocellular Carcinoma Unmet Needs

18. Hepatocellular Carcinoma Future Perspectives

19. Hepatocellular Carcinoma Analyst Review

20. Appendix

21. Report Methodology

Latest Report:

Urolithiasis market [https://www.delveinsight.com/report-store/urolithiasis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

DelveInsight's "Urolithiasis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Urolithiasis, historical and forecasted epidemiology as well as the Urolithiasis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hepatocellular-carcinoma-pipeline-analysis-2024-fda-approvals-clinical-trials-therapies-mechanism-of-action-route-of-administration-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/asco-conference-coverage



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hepatocellular Carcinoma Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight here

News-ID: 3574451 • Views:

More Releases from ABNewswire

How to Pick the Best Online Chemistry Tutoring Platform
How to Pick the Best Online Chemistry Tutoring Platform
Image: https://www.abnewswire.com/upload/2025/10/814f4b38d9855ce5fcc0509bfebaa240.jpg Choosing the right chemistry tutoring platform can make the difference between academic success and continued struggles with complex reactions and molecular structures. With students increasingly turning to digital solutions for personalized learning support, the online chemistry tutoring market has exploded with options promising everything from AI-powered progress tracking to virtual lab experiences that transform how learners approach this challenging subject. Essential Platform Features for Effective Online Chemistry Tutoring Modern chemistry tutoring
Chronic Myeloid Leukemia Pipeline Drugs Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight
Chronic Myeloid Leukemia Pipeline Drugs Report 2025: Emerging Therapies, Clinica …
DelveInsight's "Chronic Myeloid Leukemia Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Chronic Myeloid Leukemia pipeline landscape. It covers the Chronic Myeloid Leukemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myeloid Leukemia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Curious
Diabetic Retinopathy Pipeline Drugs Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight
Diabetic Retinopathy Pipeline Drugs Report 2025: Emerging Therapies, Clinical De …
DelveInsight's, "Diabetic Retinopathy Pipeline Insights 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by
Diabetic Macular Edema Pipeline Outlook Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight
Diabetic Macular Edema Pipeline Outlook Report 2025: Emerging Therapies, Clinica …
DelveInsight's, "Diabetic Macular Edema Pipeline Insight 2025" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the Diabetic Macular Edema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Macular Edema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our

All 5 Releases


More Releases for Hepatocellular

Laboratory-Produced Molecule In The Hepatocellular Carcinoma Drugs Market Indust …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Hepatocellular Carcinoma Drugs Market Size Valuation Forecast: What Will the Market Be Worth by 2025? The market size for drugs used in hepatocellular carcinoma has seen significant expansion in the past few years. The market, which is predicted to rise from $1.16 billion in 2024 to $1.27 billion in
Rising Occurrence Of Hepatocellular Carcinoma Fuels Growth In The Hepatocellular …
The Hepatocellular Carcinoma Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Hepatocellular Carcinoma Drugs Market Size During the Forecast Period? The Hepatocellular Carcinoma Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025
Hepatocellular Carcinoma Pipeline 2024
DelveInsight, "Hepatocellular Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Request a sample and discover the recent
Hepatocellular Carcinoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Hepatocellular Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Hepatocellular
Hepatocellular Carcinoma Market - Winning the Battle Against Hepatocellular: Bre …
Newark, New Castle, USA: The "Hepatocellular Carcinoma Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Hepatocellular Carcinoma Market: https://www.growthplusreports.com/report/hepatocellular-carcinoma-market/8027 This latest report researches the industry structure, sales, revenue,
Hepatocellular Carcinoma Market Insights, Forecast to 2030
The report extensively examines the global Hepatocellular Carcinoma market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Hepatocellular Carcinoma . For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the global market